- Home
- SUPN vs PAR Comparison
SUPN vs PAR Comparison
Compare SUPN & PAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- PAR
- Stock Information
- Founded
- SUPN 2005
- PAR 1968
- Country
- SUPN United States
- PAR United States
- Employees
- SUPN N/A
- PAR N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- PAR Office Equipment/Supplies/Services
- Sector
- SUPN Health Care
- PAR Miscellaneous
- Exchange
- SUPN Nasdaq
- PAR Nasdaq
- Market Cap
- SUPN 1.9B
- PAR 2.2B
- IPO Year
- SUPN 2012
- PAR N/A
- Fundamental
- Price
- SUPN $35.57
- PAR $72.34
- Analyst Decision
- SUPN Hold
- PAR Strong Buy
- Analyst Count
- SUPN 1
- PAR 8
- Target Price
- SUPN $36.00
- PAR $77.38
- AVG Volume (30 Days)
- SUPN 422.4K
- PAR 543.3K
- Earning Date
- SUPN 11-04-2024
- PAR 11-08-2024
- Dividend Yield
- SUPN N/A
- PAR N/A
- EPS Growth
- SUPN 130.79
- PAR N/A
- EPS
- SUPN 1.07
- PAR N/A
- Revenue
- SUPN $651,972,000.00
- PAR $453,986,000.00
- Revenue This Year
- SUPN $7.82
- PAR N/A
- Revenue Next Year
- SUPN N/A
- PAR $20.03
- P/E Ratio
- SUPN $33.25
- PAR N/A
- Revenue Growth
- SUPN 6.79
- PAR 49.11
- 52 Week Low
- SUPN $25.53
- PAR $35.96
- 52 Week High
- SUPN $39.37
- PAR $76.10
- Technical
- Relative Strength Index (RSI)
- SUPN 53.46
- PAR 71.56
- Support Level
- SUPN $35.87
- PAR $58.45
- Resistance Level
- SUPN $39.37
- PAR $76.10
- Average True Range (ATR)
- SUPN 1.69
- PAR 2.54
- MACD
- SUPN 0.03
- PAR 0.88
- Stochastic Oscillator
- SUPN 36.03
- PAR 78.70
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About PAR PAR Technology Corporation
PAR Technology Corp together with its subsidiaries provides management technology solutions including software, hardware, and related services, integral to the point-of-sale infrastructure and task management, information gathering, assimilation, and communication services. It has two segments. The restaurant/ Retail segment provides point-of-sale and management technology solutions such as hardware, software, and integrated technical solutions to the restaurant and retail industries. The government segment provides intelligence, surveillance, and reconnaissance solutions and mission systems support. The company derives the majority of its revenues from the Restaurant/ Retail segment.